Expression level of Flot-2 protein has correlated with poor prognosis both in lung SCC and ADC patients suggesting that Flot-2, associated with increased EGFR may serve as biomarker for indicating poor prognosis and potential therapeutic target for NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.